Apotea AB (publ) Stock: price and insider trades · Sweden

This page follows insider dealings at Apotea AB (publ) as filed with Finansinspektionen, a company from the Health Care sector. Over the twelve months to 18 October 2026, 15 filings were filed, from 12 insiders.

The flow runs one way only: 11 insiders bought (14 purchases totalling €3.5M) and nobody sold on the market. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Pär Svärdson filed the largest purchase, €2.8M, on 4 February 2026, which represents 0.41% of the company's market value. The buyers include 5 board members, 3 chief executives and 2 senior executives.

In all, 9 purchases were made within 30 days of a purchase by another insider of the company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The last insider purchase was made public on 28 July 2026, 81 days ago. The median gap between trade and publication is zero days: most filings appear on the same day. For comparison, MAR article 19 gives managers three business days to notify a trade.

Compared with its exchange (885 companies, median 7 filings), a count of 15 filings is above the norm. Our records for Apotea AB (publ) go back to 2025, with 14 purchases and no sales on the open market in total.

For comparison within the same sector, see the insider buying recorded at MAIA Biotechnology, Inc. and Cooper Companies, Inc. This summary is built from Finansinspektionen disclosures alone and does not predict where the share price will go.